Artal Group S.A. Passage Bio, Inc. Transaction History

Artal Group S.A.

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2020 Feb 11, 2021	SELL	$14.28 - $29.73 $223,453 - $465,215	-15,648 Closed	0 $0
Q3 2020 Nov 13, 2020	SELL	$12.39 - $26.15 $2.71 Million - $5.71 Million	-218,352 Reduced 93.31%	15,648 $205,000
Q2 2020 Aug 14, 2020	SELL	$14.59 - $36.07 $233,440 - $577,120	-16,000 Reduced 6.4%	234,000 $6.4 Million
Q1 2020 May 14, 2020	BUY	$8.86 - $22.2 $2.22 Million - $5.55 Million	250,000 New	250,000 $3.94 Million

38.7M

7.7K

Ticker PASG
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 54,463,200
Market Cap $35.9M
Description
Passage Bio, Inc., a genetic medicines company, develops transformative therapies for central nervous system diseases. It develops PBGM01, which utilizes a proprietary, AAVhu68 capsid to deliver to the brain and peripheral tissues a functional GLB1 gene encoding lysosomal acid beta-galactosidase for infantile GM1; PBFT02, which utilizes an AAV1 ...

Get notified when there are updates to the investment portfolio of Artal Group S.A., based on Form 13F filings with the SEC.

Stay updated on Artal Group S.A. with notifications on news.